Value20202021202220232024TTMSelling/general/admin expenses37.25 M53.75 M90.19 M47.58 M37 M33.07 MResearch & development94.25 M249.24 M187.65 M86.68 M75.62 M56.83 MOperating income-124.08 M-301.22 M-267.57 M-143.94 M-112.4 M-89.72 MNon-Operating Income, Total2.81 M-1.89 M-1.95 M-5.73 M1.39 M-6.84 MInterest expense, net of interest capitalized8.7 M1.94 M1.25 M1.22 M177.83 K0Non-Operating Income, excl. Interest Expenses-5.19 M-4.17 M657.63 K-2.24 M4.38 M-2.29 MUnusual income/expense-704.9 K343.37 K-3.86 M-4.71 M-3.16 M-4.55 MPretax income-162.89 M-303.22 M-277.65 M-135.12 M-107.25 M-179.84 MEquity in earnings-4.58 M-434.39 K-2.17 M0——Taxes00000—Non-controlling/minority interest-1.06 M00———After tax other income/expense——————Net income before discontinued operations166.4 M303.7 M279.8 M135.1 M-107.25 M-108.09 MDiscontinued operations——————Net income166.4 M303.7 M279.8 M135.1 M-107.25 M-108.09 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders166.4 M303.7 M279.8 M135.1 M-107.25 M-108.09 MBasic earnings per share (Basic EPS)—-17.4-14.04-6.09-3.95-2.55Diluted earnings per share (Diluted EPS)—-17.4-14.04-6.09-3.95-2.55Average basic shares outstanding—17.4 M19.89 M22.17 M27.16 M156.77 MDiluted shares outstanding—17.4 M19.89 M22.17 M27.16 M156.77 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)3.55 M3.52 M4.2 M2.75 M1.8 M1.54 M
Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development.